Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2006 3
2007 3
2008 7
2009 4
2010 5
2011 6
2012 6
2013 8
2014 6
2015 3
2016 1
2017 2
2020 2
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Results by year

Filters applied: . Clear all
Page 1
Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations.
Shankar G, Arkin S, Cocea L, Devanarayan V, Kirshner S, Kromminga A, Quarmby V, Richards S, Schneider CK, Subramanyam M, Swanson S, Verthelyi D, Yim S; American Association of Pharmaceutical Scientists. Shankar G, et al. Among authors: schneider ck. AAPS J. 2014 Jul;16(4):658-73. doi: 10.1208/s12248-014-9599-2. Epub 2014 Apr 24. AAPS J. 2014. PMID: 24764037 Free PMC article.
Monoclonal antibodies--regulatory challenges.
Schneider CK. Schneider CK. Curr Pharm Biotechnol. 2008 Dec;9(6):431-8. doi: 10.2174/138920108786786394. Curr Pharm Biotechnol. 2008. PMID: 19075683 Review.
Biosimilars-why terminology matters.
Weise M, Bielsky MC, De Smet K, Ehmann F, Ekman N, Narayanan G, Heim HK, Heinonen E, Ho K, Thorpe R, Vleminckx C, Wadhwa M, Schneider CK. Weise M, et al. Among authors: schneider ck. Nat Biotechnol. 2011 Aug 5;29(8):690-3. doi: 10.1038/nbt.1936. Nat Biotechnol. 2011. PMID: 21822237 No abstract available.
Biosimilars: what clinicians should know.
Weise M, Bielsky MC, De Smet K, Ehmann F, Ekman N, Giezen TJ, Gravanis I, Heim HK, Heinonen E, Ho K, Moreau A, Narayanan G, Kruse NA, Reichmann G, Thorpe R, van Aerts L, Vleminckx C, Wadhwa M, Schneider CK. Weise M, et al. Among authors: schneider ck. Blood. 2012 Dec 20;120(26):5111-7. doi: 10.1182/blood-2012-04-425744. Epub 2012 Oct 23. Blood. 2012. PMID: 23093622 Free article. Review.
Maintaining 'standards' for biosimilar monoclonal antibodies.
Prior S, Metcalfe C, Hufton SE, Wadhwa M, Schneider CK, Burns C. Prior S, et al. Among authors: schneider ck. Nat Biotechnol. 2021 Mar;39(3):276-280. doi: 10.1038/s41587-021-00848-0. Nat Biotechnol. 2021. PMID: 33664522 No abstract available.
Biosimilars in rheumatology: the wind of change.
Schneider CK. Schneider CK. Ann Rheum Dis. 2013 Mar;72(3):315-8. doi: 10.1136/annrheumdis-2012-202941. Ann Rheum Dis. 2013. PMID: 23390018 Free article. No abstract available.
TGN1412--a regulator's perspective.
Schneider CK, Kalinke U, Löwer J. Schneider CK, et al. Nat Biotechnol. 2006 May;24(5):493-6. doi: 10.1038/nbt0506-493. Nat Biotechnol. 2006. PMID: 16680120 No abstract available.
The risks of risk aversion in drug regulation.
Eichler HG, Bloechl-Daum B, Brasseur D, Breckenridge A, Leufkens H, Raine J, Salmonson T, Schneider CK, Rasi G. Eichler HG, et al. Among authors: schneider ck. Nat Rev Drug Discov. 2013 Dec;12(12):907-16. doi: 10.1038/nrd4129. Epub 2013 Nov 15. Nat Rev Drug Discov. 2013. PMID: 24232377 Review.
Manufacturing, characterization and control of cell-based medicinal products: challenging paradigms toward commercial use.
Salmikangas P, Menezes-Ferreira M, Reischl I, Tsiftsoglou A, Kyselovic J, Borg JJ, Ruiz S, Flory E, Trouvin JH, Celis P, Ancans J, Timon M, Pante G, Sladowski D, Lipnik-Stangelj M, Schneider CK. Salmikangas P, et al. Among authors: schneider ck. Regen Med. 2015;10(1):65-78. doi: 10.2217/rme.14.65. Regen Med. 2015. PMID: 25562353 Review.
57 results